Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038829 · ClinicalTrials.gov registry record · Phase 2
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
A Phase 2 study, sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT02038829: Completed Phase 2 study, sponsored by Sunovion Respiratory Development.
NCT02038829 is a Phase 2 study that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02038829, a Phase 2 study, has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
Primary Outcome
Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period. The FEV1 values within 6 hours after the use of rescue medication were considered as missing. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period
Interventions
- DRUG Placebo
- DRUG SUN101 3 mcg
- DRUG SUN-101 6.25 mcg
- DRUG SUN-101 12.5 mcg
- DRUG SUN-101 50 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
What the finished NCT02038829 record still lists
NCT02038829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02038829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02038829 about?
NCT02038829 is a clinical study titled "A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD". Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
What is the current status of trial NCT02038829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2014-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02038829?
The interventions under investigation include: Placebo (DRUG), SUN101 3 mcg (DRUG), SUN-101 6.25 mcg (DRUG), SUN-101 12.5 mcg (DRUG), SUN-101 50 mcg (DRUG).
Who is sponsoring clinical trial NCT02038829?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02038829's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia